Immupharma Plc (IMM)

ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which ... ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocrinology, and neurology; and CDx, a companion diagnostic, which is in clinical trial for the identification of immune endotype and treatment of various autoimmune diseases. The company is also involved in the development of Kapiglucagon, a proprietary glucagon prodrug, which is in pre-clinical trial for the treatment of type 1 diabetes; BioAMB, an amphotericin-B therapy, which is in pre-clinical trial for the treatment of invasive fungal infections, such as aspergillosis; and BioCIN, a vancomycin-based therapy, which is in pre-clinical trial for the treatment of gram-positive infections comprising methicillin-resistant staphylococcus aureus, sepsis, lower respiratory tract infections, osteomyelitis, and skin infections. It has collaboration arrangements with Avion Pharmaceuticals LLC and Centre National de la Recherche Scientifique for the development of P140 platform. The company was founded in 1999 and is headquartered in London, the United Kingdom. Mehr anzeigen